Ischemic Heart Disease Before Surgery: Looking Beyond the Stent

A prior PCI confirms the presence of coronary artery disease. The goal of perioperative assessment is not to review the stent — it is to assess how stable that disease is today.

Key points

A prior PCI confirms the presence of coronary artery disease. The relevant question is how stable that disease is today — not how long ago the PCI was performed.
Assessment follows five questions: why was PCI performed, when were symptoms last present, what is functional capacity, when was the last cardiac evaluation, and what medications are being used.
Functional capacity often provides more clinically useful information than stent age. Adequate FC is a meaningful indicator of current disease stability.
RCRI quantifies statistical risk — it does not assess disease stability. FC and RCRI are complementary, not interchangeable.
Antiplatelet therapy management is one part of the assessment — important, but not the whole picture. Assess the disease first.

When to use this page

When evaluating a patient with known IHD or prior PCI and you want to understand the full assessment framework. When the default response is to ask about antiplatelets before evaluating the disease.

Why CAD matters before non-cardiac surgery

Key point

The physiologic stress of non-cardiac surgery can disrupt the balance between myocardial oxygen supply and demand. In patients with coronary artery disease, the margin for that disruption is smaller. The goal of preoperative assessment is to understand how much margin this patient has — not simply to confirm that disease exists.

Non-cardiac surgery imposes cardiovascular stress through hemodynamic shifts, the inflammatory response, anemia, hypoxia, and tachycardia. In patients with stable CAD and adequate cardiovascular reserve, this stress is typically tolerable. In patients with unstable disease or limited reserve, the same stress can tip the balance toward ischemia or infarction. The assessment question is not 'does this patient have CAD?' — it is 'how stable is that disease today?'

What a prior PCI actually tells us

Key point

A prior PCI tells us one thing: coronary artery disease was significant enough to warrant intervention at some point in the past. It does not tell us whether that disease is stable today, or what the cardiovascular reserve looks like now.

The stent is a historical artifact of a past treatment decision. Perioperative assessment must go beyond it. Stent age, stent type, and antiplatelet status are all relevant — but they follow from, not substitute for, an assessment of current disease stability.

The five key questions

① Why was PCI performed? ACS (unstable angina, MI) or stable angina?
② When were symptoms last present? Chest pain, exertional dyspnea, reduced exercise tolerance?
③ Is functional capacity adequate? Can the patient achieve 4 METs? Consider DASI.
④ When was the last cardiac evaluation? Echocardiogram, post-PCI follow-up, stress testing?
⑤ What medications are being used? SAPT or DAPT? Statin, beta-blocker?

Functional capacity and disease stability

Key point

In many cases, current functional capacity provides more clinically useful information than stent age. A patient who can climb stairs, walk briskly, and has not noticed any recent decline in exercise tolerance is demonstrating meaningful cardiovascular reserve — which speaks to current stability.

Conversely, a patient who has stopped climbing stairs, avoids hills, or has noticed a progressive decline in what they can do over the past few months may be signaling disease progression — regardless of how long ago the PCI was. DASI (Duke Activity Status Index) provides a structured, reproducible estimate of functional capacity when clinical impression alone is insufficient.

RCRI and risk integration

Key point

Ischemic heart disease is one of six RCRI factors. RCRI quantifies statistical cardiovascular risk — it does not assess disease stability. FC and RCRI provide different and complementary information; neither replaces the other.

A patient with IHD, CKD, and insulin-treated diabetes carries an RCRI of 3, corresponding to approximately 10% MACE risk. That statistical risk exists regardless of how well the patient appears or how good their functional capacity is. RCRI tells us the risk burden; FC tells us the current reserve. Both must be integrated into the perioperative plan.

BNP as additional risk refinement

In patients with known IHD, BNP or NT-proBNP measurement may provide additional risk stratification, particularly when functional capacity is uncertain or reduced, or when RCRI is elevated. However, routine BNP measurement in low-risk patients has limited value (JCS 2022, ESC 2022). Use BNP as a risk signal — not as a diagnostic test or a reason to delay surgery automatically.

Antiplatelet therapy in context

Key point

Antiplatelet therapy is important — but it is one component of the overall assessment. Assess the disease first. The antiplatelet question follows.

Confirm current antiplatelet regimen: single agent (SAPT) or dual antiplatelet (DAPT)
Determine why antiplatelet therapy is being continued and what the cardiologist's intent is
Contact the managing cardiologist to confirm the perioperative antiplatelet plan
Do not modify antiplatelet therapy unilaterally

Detailed antiplatelet interruption strategies — including specific timelines, bridging therapy, and procedure-specific bleeding risk — will be covered in dedicated DAPT management tools.

Common mistakes

✗ Assuming PCI years ago means disease is resolved (stent age is not a stability indicator)
✗ Assuming asymptomatic means low risk (the patient may have simply reduced their activity level)
✗ Reviewing only the stent, not the patient (assess the disease, not the hardware)
✗ Treating antiplatelet management as the entire assessment (it is one component, not the framework)

The goal is to assess the patient, not just the stent. The central question is always: how stable is the coronary artery disease today?

Basis for this approach

ACC/AHA 2014 Guideline on Perioperative Cardiovascular Evaluation (antiplatelet therapy management section) / JCS 2022 Guidelines on Perioperative Cardiovascular Evaluation for Non-cardiac Surgery / ESC 2022 Guidelines on Cardiovascular Assessment and Management of Patients Undergoing Non-cardiac Surgery

Continue learning

Dyspnea on Stairs: Is Functional Capacity Really Adequate?

Patients often report that they are 'active' or 'walking regularly.' That does not mean they have adequate functional capacity. This case teaches how to move from symptom to functional limitation to perioperative decision.

Elevated BNP Before Surgery: A Signal, Not a Diagnosis

BNP 250 pg/mL. An elevated BNP does not diagnose heart failure. It signals that cardiac stress may be present. The key question is why it is elevated.

A Prior PCI Is Not the Whole Story: Assessing Coronary Disease Before Surgery

When a patient has a history of PCI, the first question is not about antiplatelet therapy. The first question is whether coronary artery disease remains stable today.

Back to Cardiac Education

Apply this in practice

IHD confirmed → integrate FC, RCRI, and BNP in the Navigator

Verify this decision in the tool →